Last update 29 Oct 2026

MB-11 (mAbxience)

Overview

Basic Info

Drug Type
Biosimilar
Synonyms
MB 11 (mAbxience), MB11 (mAbxience)
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Unresectable MelanomaNeoplasms
Inactive Indication-
Originator Organization
mAbxience SA
Active Organization
mAbxience Research SLmAbxience SA
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with MB-11 (mAbxience)
NCT07221734
/ RecruitingPhase 3
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
100 Clinical Results associated with MB-11 (mAbxience)
Login to view more data
100 Translational Medicine associated with MB-11 (mAbxience)
Login to view more data
100 Patents (Medical) associated with MB-11 (mAbxience)
Login to view more data
100 Deals associated with MB-11 (mAbxience)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Unresectable MelanomaPhase 3
United States
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Bosnia and Herzegovina
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Brazil
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Chile
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Greece
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Italy
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Peru
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Portugal
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Romania
mAbxience Research SL
29 Dec 2025
Unresectable MelanomaPhase 3
Slovakia
mAbxience Research SL
29 Dec 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT07221734 (LEON, ESMO2026)
Phase 3
Melanoma
First line
400
jbrnrvhmue(qjkxfhxpah) = fhlqaughag hbhojaqlzz (yvwtrgmitq )
View more
Positive
23 Oct 2026
Opdivo (EU-sourced)
jbrnrvhmue(qjkxfhxpah) = zosdvpvkue hbhojaqlzz (yvwtrgmitq )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free